Log in
Enquire now
‌

US Patent 7524852 Bicyclic pyrimidine derivatives

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
7524852
Date of Patent
April 28, 2009
Patent Application Number
10516750
Date Filed
June 6, 2003
Patent Citations Received
‌
US Patent 12024499 Muscarinic agonists
0
‌
US Patent 11773090 Pharmaceutical compounds
‌
US Patent 11834407 Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
0
‌
US Patent 11945801 Bicyclic aza compounds as muscarinic M
0
Patent Primary Examiner
‌
Mark L. Berch
Patent abstract

[wherein m and n may be the same or different and each represents an integer of 1 to 3 wherein m+n is 4 or less; R1 represents —NR4R5 (wherein R4 and R5 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl or the like); R2 represents the above Formula (II), Formula (IV) or the like; A represents a single bond, —C(═O)—, —SO2—, —OC(═O)— or the like; and R3 represents substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aralkyl or the like]

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 7524852 Bicyclic pyrimidine derivatives

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.